摘要: Small-cell lung cancer (SCLC) represents a distinct clinicopathologic entity that is biologically and clinically from non-small-cell (NSCLC). It distinguished by its rapid growth characteristics, accompanied the early development of widespread metastases. Although SCLC also extremely sensitive to both chemotherapy radiotherapy, relapse usually occurs, despite treatment within 2 yr. Overall long-term survival continues be dismal, with poor 5-yr rates approx 3–8% (1).
springer.com
sci-hub.st 参考文章(181)
A. Depierre, J. von Pawel, K. Hans, D. Moro, P. Clark, U. Gatzemeier, N. Paillot, W. Scheithauer, J. Carmichael, A. Santoro, G. Ross, M. Marangolo, 126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study Lung Cancer. ,vol. 18, pp. 35- ,(1997) , 10.1016/S0169-5002(97)89405-6
Hugh F. V. Newman, Norman M. Bleehen, Andrew Galazka, Elizabeth Scott, Small cell lung carcinoma. A phase II evaluation of r-interferon-γ Cancer. ,vol. 60, pp. 2938- 2940 ,(1987) , 10.1002/1097-0142(19871215)60:12<2938::AID-CNCR2820601215>3.0.CO;2-U
Jin S. Lee, Theera Umsawasdi, Ya-Yen Lee, Howard T. Barkley, William K. Murphy, Susan Welch, Manuel Valdivieso, Neurotoxicity in long-term survivors of small cell lung cancer International Journal of Radiation Oncology Biology Physics. ,vol. 12, pp. 313- 321 ,(1986) , 10.1016/0360-3016(86)90344-5
Hiroshi Miyamoto, Takeji Nakabayashi, Hiroshi Isobe, Hirotoshi Akita, Yoshikazu Kawakami, Takuro Arimoto, Mitsuo Asakawa, Akira Suzuki, Toshiaki Fujikane, Tetsuo Shimizu, Eiichi Sakai, A Phase III Comparison of Etoposide/Cisplatin with or without Added Ifosfamide in Small-Cell Lung Cancer Oncology. ,vol. 49, pp. 431- 435 ,(1992) , 10.1159/000227087
Patrick J. Loehrer, Susan Rynard, Rafat Ansari, Joseph Songer, Kenneth Pennington, Lawrence Einhorn, Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer Cancer. ,vol. 69, pp. 669- 673 ,(1992) , 10.1002/1097-0142(19920201)69:3<669::AID-CNCR2820690312>3.0.CO;2-V
Anthony D. Elias, Small Cell Lung Cancer: State-of-the-Art Therapy in 1996 Chest. ,vol. 112, pp. 251- ,(1997) , 10.1378/CHEST.112.4_SUPPLEMENT.251S
A. Depierre, T. Le Chevalier, E. Quoix, P. Harper, B. Milleron, M. Gottfried, V. Weestel, N. Westerhausen, P. Jacoulet, F. Le Bras, 1 Phase II trial of navelbine (NVB), in small cell lung cancer (SCLC) Lung Cancer. ,vol. 18, pp. 3- ,(1997) , 10.1016/S0169-5002(97)89280-X
EF Smit, E Fokkema, B Biesma, HJM Groen, W Snoek, PE Postmus, A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer British Journal of Cancer. ,vol. 77, pp. 347- 351 ,(1998) , 10.1038/BJC.1998.54
Elisabeth Quoix, Richard Fraser, Norman Wolkove, Harriet Finkelstein, Harvey Kreisman, Small cell lung cancer presenting as a solitary pulmonary nodule Cancer. ,vol. 66, pp. 577- 582 ,(1990) , 10.1002/1097-0142(19900801)66:3<577::AID-CNCR2820660328>3.0.CO;2-Y
Andrew T. Turrisi, Donna J. Glover, Bernard A. Mason, A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. International Journal of Radiation Oncology Biology Physics. ,vol. 15, pp. 183- 187 ,(1988) , 10.1016/0360-3016(88)90364-1